drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-T)
drug_description
An autologous BCMA-directed CAR T-cell gene therapy in which a patient's T cells are lentiviral-transduced to express a chimeric antigen receptor targeting BCMA (TNFRSF17) on malignant plasma cells, leading to CAR-mediated T-cell activation, expansion, cytokine release, and perforin/granzyme-dependent cytotoxic killing; CAR T cells may persist long term due to genomic integration.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally transduced to express a chimeric antigen receptor targeting BCMA (TNFRSF17) on malignant plasma cells. Antigen engagement triggers T‑cell activation, clonal expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of BCMA-positive cells; integrated CAR transgene enables potential long-term persistence.
drug_name
Equecabtagene autoleucel (Eque-cel)
nct_id_drug_ref
NCT07028970